Cogstate Ltd · ASX:CGS
Cogstate — Investor Presentation (July 2011)
19 slides from Cogstate's investor presentation, Jul 28, 2011
Slide 1: Patient Capital: 10 Years in Biotech
Patient Capital For personal use only 10 Years in Biotech “Dick Pratt always told me that it takes 15 years to build a good business” July 2011
Slide 2: About me - Martyn Myer
About me - Martyn Myer For personal use only • CogState Chairman and largest shareholder (19.9%) • Founding shareholder of CogState, alongside GBS Ventures • Bachelor and Masters degrees in Engineering, Masters in Business • 15 years of executive roles in two hi-technology companies – CNC profile cu
Slide 3: What drew me to CogState?
What drew me to CogState? The excitement of the science and the personal reasons & connections For personal use only Dementia is a terribly debilitating condition that impacts the lives of an increasing number of individuals and their families – including my own President 5 years Non-executive Direc
Slide 4: Commercial Market Opportunity Considerations
Commercial Market Opportunity Considerations For personal use only 1. Baby boomers are aging, thereby creating a neuroscience demographic time-bomb For the first time in history, people aged 65 and over will soon outnumber children under the age of 5. By 2050, the U.N. estimates that the proportion
Slide 5: About CogState
About CogState For personal use only Rapid, computerised tests of cognition (thinking) We measure changes in the thinking of an individual, over time Founded in 1999 and listed on the ASX in 2004 Head office in Melbourne, office in Connecticut, USA as well as UK sales presence Expertise in neuro-sci
Slide 6: Cogstate's Scientific Validation
Cogstate’s Scientific Validation For personal use only • Peer reviewed papers are CogState’s prime marketing material • CogState business opportunities are driven by the quality of our science • At this time, with over 300 publications validating our technology, we are well placed to pursue opportun
Slide 7: Clinical Trials: Commercial Validation
Clinical Trials: Commercial Validation For personal use only CogState Clinical Trial Sales Contracts US$, per annum 10,000,000 9,000,000 8,000,000 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000,000 - FY 2005 FY 2006 FY 2007 FY 2008 FY 2009 FY 2010 FY 2011 Customers now include: •
Slide 8: I've had to be patient until now
I’ve had to be patient until now For personal use only • Clinical Trials Revenue US$8m FY11 – Sales growth continues – Cost reduction strategies implemented June 2011 • FY11 result negatively impacted by strong A$ • But Operating break even result • And third consecutive year of positive cash flow •
Slide 9: My Patience Will Be Rewarded: Concussion in Sport
My Patience Will Be Rewarded For personal use only • Management of Concussion in Sport – Market opportunity developing driven by legislation and community awareness/concern – USA leading, with Australia and the rest of the world close behind – Significant revenue opportunity FY2012 and beyond – Curr
Slide 10: Sport Concussion Market for CogState
Sport Concussion Market for CogState For personal use only • CogState has had a small number of Sport customers since 2003 - elite teams (eg. AFL, international Rugby) • In the USA, State based legislation has been introduced over the last 18 months that requires concussion management programs for H
Slide 11: www.axonsports.com
For personal use only www.axonsports.com
Slide 12: Sport: Initial Success In USA
Sport: Initial Success In USA For personal use only • Mayo Clinic will offer Axon Sports tests to every High School student in Arizona • Announced in and first sales in June 2011 • Offered to over 100,000 athletes • 2011-12 school year • Mayo Clinic purchasing tests from Axon Sports but will provide
Slide 13: Sport: Initial Success in Australia
Sport: Initial Success in Australia For personal use only • Toyota will provide the Axon Sports test to 130 football clubs as part of its “Good For Footy” program • Over 25,000 grassroots footballers will have access to the test for the 2012 year, at no cost • Announced at the Australian Internation
Slide 14: My Patience Will Be Rewarded: Community Dementia Screening
My Patience Will Be Rewarded For personal use only • Community Dementia Screening – the big one! – Disease modifying drugs will be available in the future – Early diagnosis, via screening, will be critical – refer ICAD conference going on right at this moment – Paris (CGS has 4 scientists in attenda
Slide 15: Dementia Screening
Dementia Screening For personal use only Key drivers for the acceptance of cognitive screening by Primary Care Physicians: 1. USA Health care reform – part of an overall reform of Medicare (USA) – New Annual Wellness Visit, provided to Medicare recipients – Includes compulsory cognitive screening fr
Slide 16: Summary: Three Business Segments Provide Enhanced Opportunity
Summary: Three Business Segments Provide Enhanced Opportunity For personal use only Clinical Drug Concussion Dementia Screening Trials Management Description Quantify the effects of Web based test to assist in Web based test designed to drugs on human management of sports detect first signs of cogni
Slide 17: Lessons Learnt
Lessons Learnt For personal use only • Medical software business development requires long term investment, similar to drug development and hence patient capital • CogState’s Clinical Trials business: – Has achieved vital scientific validation, but it has taken time – Commercial validation from big-
Slide 18: My Other Patient Capital Investment
My Other Patient Capital Investment For personal use only Whare Kea Lodge & Chalet, Wanaka www.wharekealodge.com
Slide 19: Chairman Martyn Myer
For personal use only Chairman Martyn Myer